Clinical Trial Update: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pembrolizumab in combination with the ATL-DC vaccine for surgically accessible recurrent glioblastoma; current status is active not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ATL-DC vaccine
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Recurrent Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING